Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
- 30 November 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 11 (1) , 75-83
Abstract
Introduction: Clinical markers to predict the benefit from sorafenib in patients diagnosed with hepatocellular carcinoma (HCC) are lacking. A meta-analysis exploring the impact of development of sorafenib-related side effects on survival was conducted. Areas covered: Eligible studies included all clinical studies reporting on the survival/toxicity relationship in sorafenib-treated HCC patients. Data sources included Pub-Med, the Cochrane Controlled Trials Register, and Google scholar. After exclusion of ineligible studies, 16 studies were included in the analysis. Pooled hazard ratio (HR) for overall survival (OS) for patients developing diarrhoea vs. patients who did not was 0.42 (95% confidence interval (CI): 0.30–0.60; p < 0.00001); pooled HR for patients developing hypertension vs. those who did not was 0.46 (95% CI: 0.30–0.70; p = 0.0003); pooled HR for patients developing hand foot skin reaction vs. those who did not was 0.47 (95% CI: 0.35–0.62; p < 0.00001); pooled HR for OS for all types of skin toxicities was 0.51 (95% CI: 0.36–0.72; p = 0.0002); while pooled HR for OS for a combination of selected side effects (hypertension, HFS and diarrhoea) was 0.38 (95% CI: 0.30–0.48; p < 0.00001). No information was available regarding the impact of thyroid dysfunction or proteinuria. Expert commentary: This analysis of data demonstrated that the occurrence of sorafenib-related side effects (such as diarrhoea, hypertension and skin toxicities) is associated with a better OS in sorafenib-treated HCC patients.Keywords
This publication has 33 references indexed in Scilit:
- Clinical parameters predictive of outcomes in sorafenib‐treated patients with advanced hepatocellular carcinomaLiver International, 2013
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalysesJournal of Hepatology, 2012
- Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenibHepatology Research, 2012
- Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinomaHepatology, 2012
- Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenibBritish Journal of Cancer, 2011
- A single center experience of sorafenib in advanced hepatocellular carcinoma patientsEuropean Journal of Gastroenterology & Hepatology, 2011
- Current Strategy for Staging and Treatment: The BCLC Update and Future ProspectsSeminars in Liver Disease, 2010
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with SorafenibThe Oncologist, 2010
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2008